[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, crossover bioequivalence study of Asartan Potassium Tablets in healthy subjects under fasting and fed conditions

主要目的：比较空腹和餐后单次给药条件下，珠海润都制药股份有限公司生产的美阿沙坦钾片（规格：80mg）与Takeda Pharma A/S持证的美阿沙坦钾片（商品名：易达比®/EDARBI®，规格：80mg）在健康受试者中吸收程度和速度的差异。通过主要药代动力学参数，评价两者是否生物等效。次要目的：通过观察健康受试者单次口服受试制剂和参比制剂后的安全性指标，评价美阿沙坦钾片的安全性。

[Translation]

Primary objective: To compare the differences in the extent and rate of absorption of Asartan Potassium Tablets (specification: 80 mg) produced by Zhuhai Rundu Pharmaceutical Co., Ltd. and Asartan Potassium Tablets (trade name: EDARBI®/EDARBI®, specification: 80 mg) licensed by Takeda Pharma A/S in healthy subjects under the conditions of single administration on an empty stomach and after a meal. To evaluate whether the two are bioequivalent by the main pharmacokinetic parameters. Secondary objective: To evaluate the safety of Asartan Potassium Tablets by observing the safety indicators of the test preparation and the reference preparation after a single oral administration to healthy subjects.

Start Date15 Oct 2024

Sponsor / Collaborator

Zhuhai Rundu Pharmaceutical Co., Ltd.

CTR20243700 / CompletedNot Applicable

美阿沙坦钾片在健康受试者中餐后状态下的开放、随机、交叉生物等效性试验

[Translation] An open, randomized, crossover bioequivalence study of Asartan Potassium Tablets in healthy volunteers in the fed state

主要试验目的研究餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，浙江华润三九众益制药有限公司生产）与参比制剂美阿沙坦钾片（商品名：易达比®；规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价餐后状态口服两种制剂的生物等效性。次要试验目的评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

Main study objectives To study the pharmacokinetics of the test preparation, Asartan Potassium Tablets (Specification: 80 mg, produced by Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.) and the reference preparation, Asartan Potassium Tablets (trade name: Edabi®; Specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fed state. Secondary study objectives To evaluate the safety of the test preparation, Asartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date12 Oct 2024

Sponsor / Collaborator

Zhejiang Gaozhi Pharmaceutical Technology Co., LtdStartup

CTR20243579 / Active, not recruitingNot Applicable

美阿沙坦钾片在健康受试者中空腹/餐后状态下的开放、随机、交叉生物等效性试验

[Translation] An open, randomized, crossover bioequivalence study of Asartan potassium tablets in healthy subjects under fasting/fed conditions

主要研究目的：研究空腹/餐后状态下单次口服受试制剂美阿沙坦钾片（规格：80mg，陕西白鹿制药股份有限公司生产）与参比制剂美阿沙坦钾片（商品名：易达比®；规格：80mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂美阿沙坦钾片（规格：80mg）与参比制剂易达比®（规格：80mg）在健康受试者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation, Miasartan Potassium Tablets (Specification: 80 mg, produced by Shaanxi Bailu Pharmaceutical Co., Ltd.) and the reference preparation, Miasartan Potassium Tablets (trade name: Edabi®; Specification: 80 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary purpose of the study: to evaluate the safety of the test preparation, Miasartan Potassium Tablets (Specification: 80 mg) and the reference preparation, Edabi® (Specification: 80 mg) in healthy subjects.

Start Date09 Oct 2024

Sponsor / Collaborator

Shaanxi BAI LU Pharmaceutical Co. Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

100 Translational Medicine associated with Azilsartan Kamedoxomil

100 Patents (Medical) associated with Azilsartan Kamedoxomil

699

Literatures (Medical) associated with Azilsartan Kamedoxomil

01 Jan 2025·THERIOGENOLOGY

Dexamethasone and azithromycin enhance goat sperm preservation quality by regulating lipid metabolism

Article

Author: Ren, Chunhuan ; Zhang, Zijun ; Cao, Hongguo ; Xu, Yongjie ; Ling, Yinghui ; Sun, Shixin ; Wang, Mingyue ; Shen, Wenzheng ; Wang, Lei

Phospholipase A (PLA) in goat semen aggregates with egg yolk in semen diluent, leading to sperm death. The aim of this study is to address the issue of sperm death caused by the interaction between PLA and egg yolk, and to explore the protective effect and metabolic regulation mechanism of the combination of dexamethasone (DXMS) and azithromycin (AZM) on goat sperm under low temperature conditions. At a low temperature of 4 °C, different concentrations of DXMS were added to semen diluents containing 30 μg/mL AZM to detect the quality of goat sperm. The optimal concentration of DXMS was determined to be 20 μg/mL. On the 5th day of storage, antioxidant capacity, total cholesterol (TC) levels, energy metabolism, and metabolomics analysis were performed on the sperm of the 20 μg/mL DXMS group. The results showed that there was no aggregation caused by the interaction between PLA and egg yolk in the group containing 30 μg/mL AZM at 4 °C. 20 μg/mL DXMS significantly improved sperm motility, plasma membrane integrity, acrosome integrity, glutathione peroxidase (GPX) (P < 0.05), catalase (CAT) (P < 0.01), and superoxide dismutase (SOD) activity (P < 0.01). The content of reactive oxygen species (ROS) and Fe²⁺ significantly decreased (P < 0.01), while the content of ATP (P < 0.01) and TC (P < 0.05) significantly increased. Through metabolomics analysis, a total of 56 differential metabolites (P < 0.05) were screened, including 5a, 6-Anhydrotetracycline, Betamethasone, and 11-Dehydrocorticosterone, mainly enriched in 8 metabolic pathways (P < 0.05), including steroid hormone biosynthesis, glycerophospholipid metabolism, and choline metabolism in cancer. Among them, 5 metabolic pathways are related to lipid metabolism. The results indicate that AZM effectively inhibits the aggregation of PLA and yolk, and the combination of AZM and DXMS enhances the preservation quality of goat sperm during low-temperature preservation by regulating lipid metabolism.

01 Jan 2025·CARBOHYDRATE POLYMERS

Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections

Article

Author: Bettini, Ruggero ; Lalatsa, Aikaterini ; González-Burgos, Elena ; Serrano, D.R. ; Rodríguez, Carmina ; Anaya, Brayan J. ; Dea-Ayuela, María Auxiliadora ; Galiana, Carolina ; Serrano, Dolores R. ; Tirado, Diego F ; Sanz-Perez, Amadeo ; Tirado, Diego F. ; Serrano, Dolores R ; Anaya, Brayan J ; D'Angelo, Davide ; Molina, Gracia

Pulmonary infections are a leading cause of morbidity and mortality worldwide, a situation exacerbated by the COVID-19. Azithromycin (AZM) is used orally to treat pulmonary infections due to its ability to accumulate in lung tissues and immune cells after oral administration. Sulfated polysaccharides, such as heparin, are known to inhibit SARS-CoV-2 entry. This study presents a novel approach focused on developing a dry powder inhaler of AZM-loaded microparticles composed of either heparin or its derivatives. The microparticle formulations exhibited potent antiviral activity against SARS-CoV-2 (IC50 ≤ 95 nM) while retaining superior antibacterial efficacy against Streptococcus pneumoniae and Pseudomonas aeruginosa compared to free AZM (MIC ≤15 μg/mL). Importantly, at bactericidal concentrations, no cytotoxic effects were observed on mammalian cells, including Calu-3 cells and red blood cells. The formulations demonstrated effective alveolar aerodynamic deposition (MMAD ranging from 1 μm to 3 μm) with a Fine Particle Fraction below 5 μm close to 50 %. Adopting a conservative estimate of 20 mL for the pulmonary epithelial lining fluid volume in healthy adults, efficacious local concentrations of sulfated polysaccharides and AZM would be delivered to the lung using this multifaceted strategy which holds promise for the treatment of bacterial pulmonary infections associated with COVID-19.

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Acetazolamide and human carbonic anhydrases: retrospect, review and discussion of an intimate relationship

Review

Author: Tsikas, Dimitrios

Acetazolamide (AZM) is a strong pharmacological sulphonamide-type (R-SO₂-NH₂, pK_a 7.2) inhibitor of the activity of several carbonic anhydrase (CA) isoforms, notably of renal CA II (K_i, 12 nM) and CA IV (K_i, 74 nM). AZM is clinically used for about eighty years in various diseases including epilepsy and glaucoma. Pharmacological AZM increases temporarily the urinary excretion of bicarbonate (HCO₃^-) and sodium ions (Na⁺) and sustainably the urinary pH. AZM is excreted almost unchanged over several hours at high rates in the urine. Closely parallel concentrations of circulating and excretory AZM are observed upon administration of therapeutical doses of AZM. In a proof-of-principle study, we investigated the effects of the ingestion of a 250-mg AZM-containing tablet by a healthy volunteer on the urinary excretion of organic and inorganic substances over 5 h (range, 0, 0.5, 1, 1.5, 2, 3, 4, 5 h). Measured analytes included: AZM, amino acids and their metabolites such as guanidinoacetate, i.e. the precursor of creatine, of asymmetrically (ADMA) and symmetrically (SDMA) dimethylated arginine, nitrite (O = N-O^-, pK_a 3.4) and nitrate (O₂N-O^-, pK_a -1.37), the major metabolites of nitric oxide (NO), the C-H acidic malondialdehyde (MDA; (CHO)₂CH₂, pK_a 4.5), and creatinine for correction of analytes excretion. All analytes were measured by validated isotopologues using gas chromatography-mass spectrometry (GC-MS) methods. AZM excretion in the urine reached its maximum value after 2 h and was fairly stable for the next 3 h. Time series analysis by the ARIMA method was performed. AZM ingestion increased temporarily the urinary excretion of the amino acids Leu + Ile, nitrite and nitrate, decreased temporarily the urinary excretion of other amino acids. AZM decreased sustainably the urinary excretion of MDA, a biomarker of oxidative stress (i.e. lipid peroxidation). Whether this decrease is due to inhibition of the excretion of MDA or attenuation of oxidative stress by AZM is unknown. The acute and chronic effects of AZM on the urinary excretion of electrolytes and physiological substances reported in the literature are discussed in depth in the light of its extraordinary pharmacokinetics and pharmacodynamics. Tolerance development/drug resistance to AZM in chronic use and potential mechanisms are also addressed.

News (Medical) associated with Azilsartan Kamedoxomil

23 Dec 2020

·www.geneonline.com

China’s Hasten Biopharmaceutic Acquires Five Non-Core Assets from Japan’s Takeda

Continuing its divestiture strategy since January 2019, Takeda has planned on releasing non-core assets to focus on creating innovative therapies and developments on Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience, the 5 chosen areas that are essential to its long-term growth strategy. After the divestiture with Celltrion in early December, Takeda struck up another deal with Hasten Biopharmaceutic, a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited. Takeda is letting go of five prescription drugs, including cardiovascular and metabolism products that are mainly sold in China in exchange for around 322 million. The portfolio of select drugs generated 109.5 million net sales in 2019, mostly contributed by cardiovascular drug Ebrantil, one of the products sold to Hasten. As per the contract, the employees who are dedicated to the commercial support of these products will also be transferred to Hasten. As for the manufacturing and supply agreement, Takeda will continue to manufacture and supply the divested products to Hasten. The agreement is estimated to close by June 30, 2021, and until then, Takeda will have the full right of these products. For future use of proceeds, Takeda will firstly reduce its debt and then facilitate the R&D and expand its manufacturing capacity of these five core business areas. “This announcement marks continued progress on our commitment to simplify our global portfolio and remain focused on investing in our growth drivers, and research and development pipeline,” said Costa Saroukos, Chief Financial Officer, Takeda. “We remain committed to expansion in China with more than 15 planned approvals over the next five years. By continuing to execute and deliver on Takeda’s financial commitments, including paying down debt and focusing on our highly innovative portfolio, we can sustain our long-term growth and continue to deliver life-transforming treatments for patients worldwide.” For the past two years, Takeda has exceeded its $10 billion non-core asset divestiture target. Here are some of the divestiture agreements in 2020. March 2: Sold 30 prescription pharmaceuticals and over-the-counter (OTC) products in Near East, Middle East, and African countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for 200 million March 2: Sold 18 select OTC and prescription pharmaceutical assets in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, and Peru to Hypera Pharma for 825 million March 4: Sold 20 OTC and prescription pharmaceutical products exclusively in Russia, Georgia, and several countries from within the Commonwealth of Independent States to STADA Arzneimittel AG for 660 million. April 24: Sold 110 select OTC and prescription pharmaceutical assets in Europe to Orifarm for 670 million September 8: Sold non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm for 562 million. December 1: Sold 18 pharmaceutical products and OTC products in the Asia Pacific to Celltrion for 278 million.

Acquisition

04 Nov 2019

·www.stada.com

STADA invests $660 Million USD in Takeda’s OTC portfolio in Russia/CIS to become a major player in these branded markets

Bad Vilbel, Moscow, November 5, 2019 – STADA Arzneimittel AG (together with its subsidiaries ‘STADA’ or ‘the Group’) has agreed to acquire a portfolio of selected products from Takeda Pharmaceutical Company Limited for a total value of $660 Million USD. The portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan will be divested to STADA Arzneimittel AG. The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl, a well-known name and category leader in Russia, which is used to prevent blood clots, as well as the newer, patent-protected Nesina (for type II diabetes treatment) and Edarbi (angiotensin II receptor blocker for blood pressure control). The acquired portfolio complements STADA’s existing portfolio and capabilities in Russia which include medicines from 16 of 20 therapeutic groups of the best-selling products in retail pharmacies. The transaction will enable the Group to continue expanding its consumer health business in Russia and the CIS. It is expected that the highly capable approximately 500-strong sales and marketing team from Takeda’s business will transfer to STADA on completion of the transaction, which is expected in the first quarter of 2020. In addition, Takeda and STADA will enter into manufacturing and supply agreements in connection with the acquisition under which Takeda will continue to supply the products to STADA. The acquisition is expected to be financed by new debt financing. Peter Goldschmidt, CEO of STADA, commented: “This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market. This transaction also reflects the ambitions of STADA as we continue expanding the business internationally – both organically and through acquisitions – and continue generating significant operating efficiencies worldwide. STADA’s branded products are already well-represented in the most popular pharmacy categories in our key markets. However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments.” Advisers to STADA on this transaction included: Nomura (M&A) and Kirkland & Ellis LLP (legal). About STADA Arzneimittel AG STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

AcquisitionBiosimilar

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	EU	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	IS	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	LI	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	NO	Takeda Pharma A/S	07 Dec 2011
Hypertension	US	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	US	Takeda Pharmaceutical Co., Ltd.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02541669 (CTgov)	Phase 1	Hypertension	64	TAK-491 (Open Label: TAK-491 40 mg)	rsbvbgmfrb(iaumlkypzz) = qatjbtnnsp ynhnegtvok (fvakzcinuz, enooedcokm - aajparqwgu) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	rsbvbgmfrb(iaumlkypzz) = tobqyxchfa ynhnegtvok (fvakzcinuz, omycgpkjat - wpuhhiaujm) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	blltfeaxez(jlvzwrlnbe) = qywqoeaozx yrkziaauux (fysbfntexa, ltvvuhntdr - ufdbmejruz) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	woixoowkai(sghlycwemd) = uxovmpyude bbyfurgbjw (tosrpzertl, eleglcjfro - rvjqtfdtyl) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	woixoowkai(sghlycwemd) = bdaskhjops bbyfurgbjw (tosrpzertl, gakrqsfcyb - dyejkylvpu) View more
NCT02203916 (CTgov)	Phase 3	Essential Hypertension	328	Azilsartan medoxomil placebo (Placebo)	hphjyelgts(pawadzazqk) = wntzmntdbf gmwzseoaat (ucbyjrkcpi, xsgperakeb - wywqbaueyg) View more	-	19 Dec 2016
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	hphjyelgts(pawadzazqk) = icilkwombd gmwzseoaat (ucbyjrkcpi, wzltpprfcl - uyzicwthmn) View more
NCT00695955 (Pubmed \| Clin Exp Hypertens) Manual	Phase 3	Essential Hypertension	669	chlorthalidone+azilsartan medoxomil	icrcqyaesy(bxnrgfmnbw) = boooccnxtl htxvyjbsft (jtfptunctv ) View more	Positive	01 Jan 2016
				hydrochlorothiazide+azilsartan medoxomil	icrcqyaesy(bxnrgfmnbw) = hucfiglvtb htxvyjbsft (jtfptunctv ) View more
NCT01496430 (CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Hypertension	105	Placebo (Placebo QD)	haqtkdysrm(ndjgtokfjf) = bukaejmbfp vpohxmhqka (bylvntkuvh, lvznjkwtof - ntsqjhcmzj) View more	-	06 May 2015
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg QD)	haqtkdysrm(ndjgtokfjf) = lzqsevjsna vpohxmhqka (bylvntkuvh, rjxvrdkeeh - cpcxzzqkyn) View more
NCT00696384 (Pubmed) Manual	Phase 3	Hypertension	418	Azilsartan Medoxomil	hxfzjkwehz(vpwvceiaan): difference = -7.8 (95% CI, -9.8 to -5.8), P-Value = <0.001 View more	Positive	01 Mar 2015
				Azilsartan Medoxomil+Chlorthalidone
NCT01078376 (CTgov)	Phase 1	Hypertension	29	Azilsartan medoxomil (TAK-491)	aqxbcqxscs(khpqzrgzwy) = wfrudpglyy mdhmfmfzag (uhdbptwkoq, qjqtepvvsc - dnyqzcilic) View more	-	25 Jul 2014
NCT00696384 (CTgov)	Phase 3	Essential Hypertension	418	Azilsartan Medoxomil (Azilsartan Medoxomil QD - Double Blind Reversal Phase)	xvgzexsimx(erggknjvgi) = nxdfugtqek osjedqxvhn (ctgnbhlydq, ehhymcrxsu - eiqufaytyl) View more	-	04 Jan 2012
				Placebo (Placebo QD - Double Blind Reversal Phase)	xvgzexsimx(erggknjvgi) = mtetgfscbi osjedqxvhn (ctgnbhlydq, bfszupgtec - gfwdzsfxyb) View more
NCT00591578 (Pubmed \| J Clin Hypertens (Greenwich))	Phase 3	Essential Hypertension	984	Azilsartan medoxomil (AZL-M)	lxaimzuvto(smdchawmuc) = zfxpoqptxy wevdfaicxl (nmcqmkdyhb )	Positive	01 Jul 2011
				Valsartan (VAL)	lxaimzuvto(smdchawmuc) = rymarnixae wevdfaicxl (nmcqmkdyhb )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis